ALB and neoplasm: However, another kind of process enables to yield no-carrier-added (n.c.a.)[131I]mIBG, with a very high specific activity (1600 mCi/mol, HSA) allowing a more potent therapeutic dose that is less likely to saturate receptors on tumor cells, thereby resulting in an increased cytotoxic activity [156].